Stimulant Use Disorders

The Clinical Practice Guideline on the Management of Stimulant Use Disorder is being developed to provide information on evidence-based strategies and standards of care for the prevention and treatment of stimulant use disorders (StUD), stimulant intoxication, and stimulant withdrawal.

This document draws on existing empirical evidence and clinical judgment with the goal of improving the quality of care for people with StUD.

Public Comment

ASAM and AAAP are accepting public comment on the draft guideline until May 31, 2023. Comments should be submitted through the survey link below.

Review Instructions

1. Download the draft guideline

The guideline is being developed using the GRADE methodology. In accordance with this methodology, evidence-to-decision (EtD) tables have been developed for the recommendation statements and provide an overview of the research that was considered and considerations of the guideline committee. The EtD tables can be found here.

2. Provide Comments

Comments will be collected through a survey [see link below] to facilitate the reconciliation of feedback. A preview of the survey can be found here. When providing your comments, please include the page and line number (not a range, just a single number) in the appropriate boxes. If your comment refers to a range of line numbers, you only need to indicate the first line number within the range. To make a general comment about the document as a whole, put 0 for page and line numbers. You can provide up to 100 comments. If you would like to provide additional comments, you can submit the survey again. Feedback must be submitted through this survey to be considered.

Note: The system does not allow you to save your progress to return later. Always submit your response before exiting. If you have additional comments at a later time, you can reenter the survey and submit a new response.

3. Complete a conflict of interest (COI) disclosure form

ASAM requires all guideline reviewers to disclose relevant relationships and potential COI. Please complete ASAM's disclosure form in order for your comments to be considered. If you have any questions, please contact Taleen Safarian at tsafarian@asam.org.

Thank you in advance for your participation in this important initiative. We look forward to your feedback.